A recent study conducted by Dr. med. Michael Winkelmann and his colleagues at the LMU Klinikum München explored the association between TGR dynamics from pre-treatment to post-treatment imaging and the patients' outcomes.
The research provides valuable insights into the potential of TGR as a novel prognostic imaging biomarker in the context of CAR-T therapy for patients with relapsed or refractory non-Hodgkin's lymphoma.

Study with mint Lesion™ Uncovers the Impact of Tumor Growth Rate in Predicting the Efficacy of CAR-T-cell Therapy in Lymphoma Patients
Related Resources
Related Resources

LMU University Hospital: Artificial Intelligence for TNM Staging in NSCLC – How Reliable Are AI-Based Segmentations?
The recent study “Artificial intelligence for TNM staging in NSCLC – a critical appraisal of segmentation utility in [¹⁸F]FDG PET/CT” provides a…

Successful “RECIST and Beyond” Workshop in Cologne: Advancing Precision in Oncologic Imaging
How can complex tumor findings be assessed accurately, reproducibly, and in line with clinical guidelines?

Implementing RANO 2.0 for Neuro-Oncology Clinical Trials in mint Lesion
Tumor response assessment in neuro-oncology clinical trials requires careful attention to measurement protocols and confirmation scan requirements. To…